France-based Flamel Technologies and Merck Serono have shook hands
on a new €2m ($2.9m) deal which would see Flamel's Medusa
technology used to develop an extended-release profile of an
undisclosed therapeutic protein.
Wyeth has signed a license agreement with French firm Flamel
Technologies to apply the company's second innovative drug delivery
technology to one of its protein therapeutics.
As it prepares for the launch of GlaxoSmithKline's beta-blocker
Coreg (carvedilol) with a controlled release formulation, drug
delivery company Flamel saw its bottom line, in the absence of new
partners, shift deep into the red...
A $30.1m drop in licence and research revenue and the expensive
removal by rebel shareholders of its former CEO Gerard Soula last
June have taken drug delivery company Flamel from a net profit of
$12.5m (€10.3m) in 2004 to a net loss...
News that B-MS has dropped out of an agreement to develop Basulin,
an improved formulation of insulin which was the subject of a $165
million deal - including $20 million upfront - between the two
companies last year.
GlaxoSmithKline has entered into a new drug formulation agreement
with Flamel Technologies of France that could see the latter firm
receive up to $45 million (€41.3m) in licensing fees and milestone
payments.